Hi Sly and the family Stone
This is in now way meant to be a bubble popper for how great this product could be for impugne, but I thought I would point out a few things I have learnt from painful experience.
these are things I am sure you are aware of, but perhaps lesser experienced investors reading your post might not be aware of.
Cancer therapy trials are complex. It is worth reading up on the structure, cost and probability of success of each particular stage trial any therapeutic agent needs to go through.
this is true for any drug but cancer trials have additional issues to consider.
A drug to treat a simple infection, say tonsillitis, has key advantages to trial in comparison to cancer agents.
Tonsillitis will resolve, or not resolve, in response to a treatment in a week. Trials are short and easy to measure.
cancers are much more complex. Trials will measure things like “disease free interval”, “time to clinical progression” , “tumour volume” and so on. These are quicker to measure (months) but don’t actually measure anything particularly important.
The gold standard outcome is survival. 1 year, 2 year, 5 year survival rates. To measure these tales, well, 1,2 or 5 years!
And big numbers of patients to measure anything meaningful.
So, in summary there might be some intermediate encouraging updates in th coming months but there won’t be anything conclusive for…. you guessed it.
Further, intermediate markers of success that seem really encouraging often do not translate into clinically meaningful outcomes.
good luck to all!
